News & Updates

Show Multimedia Only
Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir

Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir

30 Apr 2024 byMike Ng

Treating COVID-19 patients who had been vaccinated or did not have risk factors for severe disease with ritonavir-boosted nirmatrelvir (nirmatrelvir–ritonavir) did not expedite the time to symptom alleviation, reported investigators in the EPIC-SR trial.

30 Apr 2024
Subcutaneous atezolizumab favoured over intravenous infusion

Subcutaneous atezolizumab favoured over intravenous infusion

18 Apr 2024 byJairia Dela Cruz

Nonsmall cell lung cancer (NSCLC) patients with high PD-L1 expression appear to show a strong preference for receiving atezolizumab subcutaneously rather than intravenously.

18 Apr 2024
Anlotinib plus etoposide/carboplatin improves survival in extensive-stage SCLC

Anlotinib plus etoposide/carboplatin improves survival in extensive-stage SCLC

18 Apr 2024 byStephen Padilla

Use of anlotinib combined with etoposide and carboplatin (EC; chemotherapy) as first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC) yields a significantly improved progression-free survival (PFS) as well as overall survival (OS) benefits when compared with chemotherapy, according to data from the phase III ETER701 trial presented at ELCC 2024.

18 Apr 2024